Probiodrug is a technology leader with an experienced management team and a very solid know-how and IP position on novel inhibitors for disease relevant enzymes. The Company has a convincing approach to block of Glutaminyl Cyclase as therapeutic target in Alzheimer's Disease and Cancer Immunotherapy. The new investor consortium recognizes the significance of Probiodrug's scientific approach and the diligent clinical work the team has performed in preparation of the Phase 2b program for its lead compound PQ912.", commented Dr. Claus Christiansen, Leader of the consortium and Chairman of the Board of Nordic Bioscience.